NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free CVM Stock Alerts $1.27 -0.13 (-9.29%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.4150-Day Range$1.30▼$2.2152-Week Range$1.04▼$3.23Volume471,177 shsAverage Volume458,676 shsMarket Capitalization$68.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get CEL-SCI alerts: Email Address Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About CEL-SCI Stock (NYSE:CVM)CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More CVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVM Stock News HeadlinesMay 11, 2024 | insidertrades.comInsider Buying: CEL-SCI Co. (NYSE:CVM) Director Acquires 20,000 Shares of StockMay 10, 2024 | insidertrades.comCEL-SCI Co. (NYSE:CVM) SVP Acquires $11,120.00 in StockMay 16 at 9:00 AM | businesswire.comCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsMay 13, 2024 | americanbankingnews.comCEL-SCI Co. (NYSE:CVM) Director Buys $27,800.00 in StockMay 8, 2024 | msn.comCEL-SCI gains as FDA greenlights confirmatory study for MultikineMay 8, 2024 | businesswire.comCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerApril 23, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 16, 2024 | businesswire.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentApril 15, 2024 | finance.yahoo.comCVM: Parallel Engagement on Four FrontsApril 12, 2024 | msn.comScientists produce in vitro model of cell differentiation during early facial developmentApril 9, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 6, 2024 | seekingalpha.comCVM CEL-SCI CorporationMarch 28, 2024 | msn.comCross-species insights: Study finds calcium link in plant and animal immunityMarch 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugSee More Headlines Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today5/19/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CVM CUSIPN/A CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-218.00% Return on Assets-98.53% Debt Debt-to-Equity Ratio0.63 Current Ratio1.67 Quick Ratio0.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book4.88Miscellaneous Outstanding Shares54,160,000Free Float45,364,000Market Cap$68.78 million OptionableOptionable Beta1.23 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Geert R. Kersten Esq. (Age 65)Chief Executive & Financial Officer, Treasurer and Director Comp: $702.79kMs. Patricia B. Prichep (Age 73)Senior VP of Operations & Corporate Secretary Comp: $295.18kDr. Eyal Talor Ph.D. (Age 68)Chief Scientific Officer Comp: $351.88kDr. Daniel H. Zimmerman Ph.D. (Age 83)Senior Vice President of Research & Cellular Immunology Comp: $46.08kMr. John Cipriano (Age 82)Senior Vice President of Regulatory Affairs Comp: $246.97kKey CompetitorsCognition TherapeuticsNASDAQ:CGTXInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILElutiaNASDAQ:ELUTProtalix BioTherapeuticsNYSE:PLXView All CompetitorsInsiders & InstitutionsTidal Investments LLCBought 13,891 shares on 5/17/2024Ownership: 0.026%Vanguard Group Inc.Bought 113,703 shares on 5/10/2024Ownership: 4.063%Geert R KerstenBought 30,000 shares on 5/8/2024Total: $41,700.00 ($1.39/share)Patricia B PrichepBought 8,000 shares on 5/8/2024Total: $11,120.00 ($1.39/share)Thoroughbred Financial Services LLCSold 70,001 shares on 5/8/2024Ownership: 0.105%View All Insider TransactionsView All Institutional Transactions CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed in 2024? CEL-SCI's stock was trading at $2.72 at the beginning of 2024. Since then, CVM stock has decreased by 53.3% and is now trading at $1.27. View the best growth stocks for 2024 here. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) posted its quarterly earnings data on Thursday, May, 16th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). What ETF holds CEL-SCI's stock? Amplify Treatments, Testing and Advancements ETF holds 12,734 shares of CVM stock, representing 0.22% of its portfolio. When did CEL-SCI's stock split? CEL-SCI's stock reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.06%), CVI Holdings LLC (1.63%), Thoroughbred Financial Services LLC (0.11%), Chilton Capital Management LLC (0.03%), Tidal Investments LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, Patricia B Prichep, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CVM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.